Peptech name change to Arana Therapeutics
Peptech has announced an official name change to Arana Therapeutics. The company’s ASX code will change to AAH this week and its code on the London Stock Exchange has been changed to AAHx.
Arana Therapeutics, created by the merger of Peptech and EvoGenix in August 2007, is focused on developing antibody/protein-based new generation products and platforms for the treatment of inflammatory diseases and cancer.
“This final step in the merger of Peptech and EvoGenix creates a true global player in the antibody therapeutics sector,” said Robin Beaumont, chairman of Arana Therapeutics.
“As well as critical mass, Arana Therapeutics has the right mix of people, skills, technologies and, most importantly, financial backing to achieve international recognition. Our key focus now is to rapidly develop our exciting product pipeline.”
Noxopharm appoints Dr Olivier Laczka CEO
Australian clinical-stage biotech company Noxopharm Limited has appointed Dr Olivier Laczka as...
Nominations now open for the 2026 NMI Measurement Awards
Until 20 May, the National Measurement Institute (NMI) is accepting nominations for the 2026 NMI...
Australia to begin treaty negotiations on association to Horizon Europe
To give Australian organisations access to the world's largest pooled research fund in 2027,...
